
News|Articles|December 1, 2023
AAO 2023: Luminopia, first FDA-approved digital therapeutic for amblyopia
Author(s)David Hutton, Sheryl Stevenson
Rupa Wong, MD, spoke with the Ophthalmology Times team about Luminopia, the first FDA-approved digital therapeutic for amblyopia at this year's American Academy of Ophthalmology meeting.
Advertisement
Rupa Wong, MD, spoke with the Ophthalmology Times team about Luminopia, the first FDA-approved digital therapeutic for amblyopia at this year's American Academy of Ophthalmology meeting.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Moorfields study reveals sharp rise in glaucoma burden across the UK
2
Why individualized glaucoma care remains essential amid uneven patient awareness
3
Study identifies corneal endothelial changes following mRNA COVID-19 vaccination
4
SpyGlass Pharma randomizes first patients in 2 phase 3 clinical trials of the BIM-IOL System
5














































